OBJECTIVE: This case report describes a patient with nocturnal bruxism and related neck pain treated with botulinum toxin type A (BTX-A). CLINICAL FEATURES: The patient was a 27-year-old man with nocturnal bruxism and difficulty in active mouth opening and chewing and neck pain at rest. His numeric pain score was 7 of 10. Surface electromyography of the temporalis and masseter muscles showed typical signs of hyperactivity, characterized by compound muscle action potential amplitude alterations. INTERVENTION AND OUTCOME: After clinical evaluation, he was treated with BTX-A to reduce masseter and temporalis muscle hyperactivity. After 3 days of treatment with BTX-A, with each masseter muscle injected with a dose of about 40 mouse units with a dilution of 1 mL and with temporal muscle bilaterally injected with 25 mouse units with the same dilution, a decrease in bruxism symptoms was reported. Neck pain also decreased after the first treatment (visual analog scale of 2/10) and then resolved completely. After 4 weeks, electromyography showed the reduction of muscle hyperactivity with a decrease in the amplitude of the motor action potential. The same reduction in signs and symptoms was still present at assessment 3 months posttreatment. CONCLUSION: These findings suggest that BTX-A may be a therapeutic option for the treatment of bruxism and related disorders.
OBJECTIVE: This case report describes a patient with nocturnal bruxism and related neck pain treated with botulinum toxin type A (BTX-A). CLINICAL FEATURES: The patient was a 27-year-old man with nocturnal bruxism and difficulty in active mouth opening and chewing and neck pain at rest. His numeric pain score was 7 of 10. Surface electromyography of the temporalis and masseter muscles showed typical signs of hyperactivity, characterized by compound muscle action potential amplitude alterations. INTERVENTION AND OUTCOME: After clinical evaluation, he was treated with BTX-A to reduce masseter and temporalis muscle hyperactivity. After 3 days of treatment with BTX-A, with each masseter muscle injected with a dose of about 40 mouse units with a dilution of 1 mL and with temporal muscle bilaterally injected with 25 mouse units with the same dilution, a decrease in bruxism symptoms was reported. Neck pain also decreased after the first treatment (visual analog scale of 2/10) and then resolved completely. After 4 weeks, electromyography showed the reduction of muscle hyperactivity with a decrease in the amplitude of the motor action potential. The same reduction in signs and symptoms was still present at assessment 3 months posttreatment. CONCLUSION: These findings suggest that BTX-A may be a therapeutic option for the treatment of bruxism and related disorders.
Authors: M Naumann; Y So; C E Argoff; M K Childers; D D Dykstra; G S Gronseth; B Jabbari; H C Kaufmann; B Schurch; S D Silberstein; D M Simpson Journal: Neurology Date: 2008-05-06 Impact factor: 9.910
Authors: D DI Venere; F Pettini; G M Nardi; A Laforgia; G Stefanachi; V Notaro; B Rapone; F R Grassi; M Corsalini Journal: Oral Implantol (Rome) Date: 2017-04-10
Authors: Giuseppe Aprile; Eleonora Ortu; Ruggero Cattaneo; Davide Pietropaoli; Mario Giannoni; Annalisa Monaco Journal: J Med Case Rep Date: 2017-12-02